ArticlePloS one2025
A clinical study exploring the prediction of microvascular invasion in hepatocellular carcinoma through the use of combined enhanced CT and MRI radiomics.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- TLCD1 correlates with malignant progression of hepatocellular carcinoma and activation of the ERK signaling cascade.Scientific reports · 2026Article
- Transformer-Based Deep Learning for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma.Cancers · 2025Article
- From texture analysis to artificial intelligence: global research landscape and evolutionary trajectory of radiomics in hepatocellular carcinoma.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo develop a predictive model for microvascular invasion (MVI) in hepatocellular carcinoma (HCC) through radiomics analysis, integrating data from both enhanced computed tomography (CT) and magnetic resonance imaging (MRI).
methodsA retrospective analysis was conducted on 93 HCC patients who underwent partial hepatectomy. The gold standard for MVI was based on the histopathological diagnosis of the tissue. The 93 patients were randomly divided into training and validation groups in 7:3 ratio. The imaging data of patients, including CT and MRI, were collected and processed using 3D Slicer to delineate the region of interest (ROI) for each tumor. Radiomics features were extracted from CT and MRI of patients using Python. Lasso regression analysis was used to select optimal radiomics features for MVI in the training group. The optimal radiomics features of CT and MRI were selected to establish the prediction model. The predictive performance of the model was evaluated using the receiver operator characteristic curve (ROC), calibration curve, and decision curve analysis (DCA).
resultsAfter univariate and multivariate analyses, it was found that tumor diameter was significantly different between the MVI positive and negative groups. After extracting 2153 imaging phenotyping features from the CT and MRI images of the 93 patients using Python, ten standardized coefficient non-zero imaging phenotyping features were finally determined by Lasso regression analysis in the CT and MRI images. A comprehensive predictive model with clinical variable and optimal radiomics features was established. The area under the curve (AUC) of the training group was 0.916 (95%CI: 0.843-1.000), sensitivity: 95.2%, specificity: 79.2%. In the validation group, the predictive model diagnosed MVI with AUC = 0.816 (95%CI: 0.642-0.990), sensitivity: 84.2%, and specificity: 75.0%.
conclusionThe joint model that integrated the optimal radiomics features with clinical variables has good diagnostic performance for MVI of HCC and specific clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.